<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203836</url>
  </required_header>
  <id_info>
    <org_study_id>LP0190-1487</org_study_id>
    <nct_id>NCT04203836</nct_id>
  </id_info>
  <brief_title>A 2-part Trial to Evaluate the Effect of Food and of Formulation on LEO 152020</brief_title>
  <official_title>A Phase 1, 2-part, Randomised, Oral Dose Trial to Evaluate the Effect of Food and Formulation on LEO 152020 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 2-part, phase 1 trial in healthy people:

      Part 1 is to evaluate different formulations on LEO 152020 and will be double-blind and
      placebo controlled using capsules.

      Part 2 is to evaluate the food effect on LEO 152020 in an open-label design using film-coated
      tablets
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 will evaluate the pharmacokinetics and tolerability of up to 3 different capsule
      formulations in different dose groups (Groups A to C). The decisions for the formulation used
      to go forward with the subsequent dose groups will be based on the observations from the
      previous dose group(s).

      Part 2 will evaluate the pharmacokinetics and tolerability of 2 single doses of film-coated
      tablets in the morning after fasting or after a high-fat breakfast. The 2 doses will be
      separated by a washout period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 (double-blind, placebo controlled) Part 2 (single dose, cross-over with food effect)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of total adverse events (AEs) and number of subjects with AEs for each dose groups</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Number of AEs per subject at each combination of treatment and in total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Cmax</measure>
    <time_frame>pre-dose to 48 hours of each treatment period (Day 1 and Day 8)</time_frame>
    <description>Maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: AUC (0 to infinity)</measure>
    <time_frame>pre-dose to 48 hours of each treatment period (Day 1 and Day 8)</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time 0 extrapolated to infinity (AUC0 inf)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with clinically relevant changes in vital signs (resting blood pressure)</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Clinically relevant changes in resting blood pressure (mmHq)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with clinically relevant changes in vital signs (pulse)</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Clinically relevant changes in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with clinically relevant changes in vital signs (oral body temperature)</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Clinically relevant changes in oral body temperature (fahrenheit/celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with laboratory abnormalities in chemistry parameters</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Clinically relevant abnormalities in any chemistry laboratory parameters tested (standard units): Sodium, potassium, creatinine, creatine phosphokinase, urea nitrogen, calcium , alkaline phosphatase , aspartate aminotransferase , alanine aminotransferase , gamma glutamyl transferase , bilirubin, lactate dehydrogenase, cholesterol, triglycerides, glucose (fasting), albumin, protein, or tryptase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with laboratory abnormalities in haematology parameters</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Clinically relevant abnormalities in any haematology laboratory parameter tested (standard units): erythrocytes, hematocrit, hemoglobin, or white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with laboratory abnormalities in urinalysis parameters</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Clinically relevant laboratory abnormalities in any urinalysis parameters (standard units): protein, glucose, ketones, occult blood, leukocytes, or nitrite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of subjects with abnormal ECGs</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Abnormal ECGs (maximum QTcF interval of ≥450 msec, or maximum change from baseline of ≥60 msec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC (0 to infinity)</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time 0 extrapolated to infinity (AUC0 inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC (0 to tau)</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Area under the plasma concentration time curve (AUC) over dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC (0 to last)</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time 0 extrapolated to infinity (AUC0 inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: tmax</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: t 1/2</measure>
    <time_frame>pre-dose to 48 hours post (last) dose</time_frame>
    <description>Terminal elimination half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of total adverse events (AEs) and number of subjects with AEs at each combination of treatment and period</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Number of AEs per subject at each combination of treatment and in total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of subjects with clinically relevant changes in vital signs (resting blood pressure)</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Clinically relevant changes in resting blood pressure (mmHq)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of subjects with clinically relevant changes in vital signs (pulse)</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Clinically relevant changes in pulse (beats per minute)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of subjects with clinically relevant changes in vital signs (oral body temperature)</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Clinically relevant changes in oral body temperature (fahrenheit/celsius)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of subjects with laboratory abnormalities in chemistry parameters</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Clinically relevant abnormalities in any chemistry laboratory parameters tested (standard units): Sodium, potassium, creatinine, creatine phosphokinase, urea nitrogen, calcium , alkaline phosphatase , aspartate aminotransferase , alanine aminotransferase , gamma glutamyl transferase , bilirubin, lactate dehydrogenase, cholesterol, triglycerides, glucose (fasting), albumin, protein, or tryptase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of subjects with laboratory abnormalities in haematology parameters</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Clinically relevant abnormalities in any haematology laboratory parameter tested (standard units): erythrocytes, hematocrit, hemoglobin, or white blood cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of subjects with laboratory abnormalities in urinalysis parameters</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Clinically relevant laboratory abnormalities in any urinalysis parameters (standard units): protein, glucose, ketones, occult blood, leukocytes, or nitrite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Number of subjects with abnormal ECGs</measure>
    <time_frame>Baseline to Day 10</time_frame>
    <description>Abnormal ECGs (maximum QTcF interval of ≥450 msec, or maximum change from baseline of ≥60 msec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC (0 to last)</measure>
    <time_frame>pre-dose to 48 hours of each treatment period (Day 1 and Day 8)</time_frame>
    <description>Area under the plasma concentration time curve (AUC) from time 0 extrapolated to infinity (AUC0 inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: tmax</measure>
    <time_frame>pre-dose to 48 hours of each treatment period (Day 1 and Day 8)</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: t 1/2</measure>
    <time_frame>pre-dose to 48 hours of each treatment period (Day 1 and Day 8)</time_frame>
    <description>Terminal elimination half life</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Group A - LEO 152020 versus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dose given once daily for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Group B - LEO 152020 versus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral dose given once daily for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Group C - LEO 152020 versus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose given after a full breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose given in fasting state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 152020 Tablet</intervention_name>
    <description>film-coated tablet</description>
    <arm_group_label>Part 2: Fasting</arm_group_label>
    <arm_group_label>Part 2: Fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 152020 Capsule</intervention_name>
    <description>capsule</description>
    <arm_group_label>Part 1: Group A - LEO 152020 versus placebo</arm_group_label>
    <arm_group_label>Part 1: Group B - LEO 152020 versus placebo</arm_group_label>
    <arm_group_label>Part 1: Group C - LEO 152020 versus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 152020 Placebo Capsule</intervention_name>
    <description>placebo capsule</description>
    <arm_group_label>Part 1: Group A - LEO 152020 versus placebo</arm_group_label>
    <arm_group_label>Part 1: Group B - LEO 152020 versus placebo</arm_group_label>
    <arm_group_label>Part 1: Group C - LEO 152020 versus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria:

          -  Body mass index (BMI) between 18.0-32.0 kg/m2 (both inclusive)

          -  In good health at screening and check-in as judged by the investigator based on
             medical history, physical examination, vital signs assessment, 12-lead ECG, and
             clinical laboratory evaluations.

          -  Pulse rate of 50 to 100 bpm at screening, or with minor deviations judged to be
             acceptable by the investigator

          -  Females of child bearing potential and male subjects whose partners are of
             child-bearing potential must also agree to use an additional effective method of
             contraception.

        Key exclusion Criteria:

          -  Subjects who do not, or whose partners do not agree to use effective method(s) of
             contraception from the time of the first dose until 3 months (90 days) after the final
             dose.

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of any drug.

          -  History of any significant infectious disease within 2 weeks prior to drug
             administration as assessed by the investigator.

          -  Subjects who have received any medication within 14 days of the first dose
             administration, except for hormonal contraception.

          -  Subjects who are still participating in a clinical trial (e.g. attending follow-up
             visits) or who have participated in a clinical trial involving administration of an
             investigational drug (new chemical entity), or a marketed drug within the past 3
             months prior to the first dose.

          -  ECG abnormalities at screening or check-in

          -  Heart rate of &lt;50 or &gt;100 beats per minute, unless the investigator judges the subject
             to be eligible for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Disclosure</last_name>
    <phone>(+1) 877-557-1168</phone>
    <email>ClinicalTrialscontactus@leo-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LEO Pharma Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD can be made available to researchers in a closed environment for a specified period of time.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data is available to request after approval of the studied indication.</ipd_time_frame>
    <ipd_access_criteria>Data-sharing is subject to approved scientifically sound research proposal and signed data-sharing agreement.</ipd_access_criteria>
    <ipd_url>http://leopharmatrials.com/for-professionals</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

